NeuroQuest Receives Investment from SCRA Technology Ventures

NeuroQuest, a Misgav Business Park, Israel-based developer of blood-based immune biomarkers, received an investment from SCRA Technology Ventures‘ SC Launch program.

The amount of the deal was not disclosed.
The SC Launch investment follows recent funding led by the North Charleston-based InterTech Group, and the Maryland/Israel Trendlines Fund, managed by the Baltimore- based Maryland/Israel Development Center. Seed financing was provided by the Misgav Venture Accelerator and Israel’s Office of the Chief Scientist.

The company will use the funds to open its Charleston, S.C.-based affiliate and clinical development center.

Led by Ilya Budik, CEO, NeuroQuest is developing blood-based immune biomarkers that produce early and accurate diagnostic and therapeutic tools for Alzheimer’s and ALS. The company is preparing for clinical studies of its diagnostic test, partnered with the Harvard Clinical Research Institute and top national research centers.



Join the discussion